aluates Reports

$ 0.0

Automative

Global Oral Anti-diabetes Drugs Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-21G10330

Global Oral Anti diabetes Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global Oral Anti-diabetes Drugs Market Research Report 2025

Code: QYRE-Auto-21G10330

Report

June 2025

Pages:96

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi

Eli Lilly

Astrazeneca plc

Astellas Pharma Inc

Boehringer Ingelheim

Merck

Takeda

Bristol–Myers Squibb

Novartis

Pfizer Inc

Abbott

Biocon Ltd.

Sunpharma

Novo Nordisk

Piramal Healthcare

Bayer HealthCare

Dr. Reddy’s Laboratories Ltd.

Glenmark Pharmaceuticals Ltd

Johnson & Johnson (Janssen Pharmaceuticals)

Oral Anti-diabetes Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Oral Anti-diabetes Drugs Market

The global market for Oral Anti-diabetes Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Oral Anti-diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-diabetes Drugs.

The Oral Anti-diabetes Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Anti-diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Anti-diabetes Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Oral Anti-diabetes Drugs Market Report

Report Metric	Details
Report Name	Oral Anti-diabetes Drugs Market
CAGR	5%
by Type	by Drug Class
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi, Eli Lilly, AstraZeneca plc, Astellas Pharma Inc, Johnson & Johnson (Janssen Pharmaceuticals), Boehringer Ingelheim, Merck, Takeda, Bristol Myers Squibb, Novartis, Pfizer, Abbott, Biocon, Sunpharma, Novo Nordisk, Piramal Healthcare, Bayer Healthcare, Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Anti-diabetes Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Oral Anti-diabetes Drugs Market report?

Ans: The main players in the Oral Anti-diabetes Drugs Market are Sanofi, Eli Lilly, AstraZeneca plc, Astellas Pharma Inc, Johnson & Johnson (Janssen Pharmaceuticals), Boehringer Ingelheim, Merck, Takeda, Bristol Myers Squibb, Novartis, Pfizer, Abbott, Biocon, Sunpharma, Novo Nordisk, Piramal Healthcare, Bayer Healthcare, Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd

What are the Application segmentation covered in the Oral Anti-diabetes Drugs Market report?

Ans: The Applications covered in the Oral Anti-diabetes Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Oral Anti-diabetes Drugs Market report?

Ans: The Types covered in the Oral Anti-diabetes Drugs Market report are by Drug Class

Recommended Reports

Diabetes Medications

Insulin & Adjacent Drugs

Oral Drug Markets

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 by Type

1.2.3 by Drug Class

1.3 Market by Application

1.3.1 Global Oral Anti-diabetes Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oral Anti-diabetes Drugs Market Perspective (2020-2031)

2.2 Global Oral Anti-diabetes Drugs Growth Trends by Region

2.2.1 Global Oral Anti-diabetes Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Oral Anti-diabetes Drugs Historic Market Size by Region (2020-2025)

2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031)

2.3 Oral Anti-diabetes Drugs Market Dynamics

2.3.1 Oral Anti-diabetes Drugs Industry Trends

2.3.2 Oral Anti-diabetes Drugs Market Drivers

2.3.3 Oral Anti-diabetes Drugs Market Challenges

2.3.4 Oral Anti-diabetes Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue

3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2020-2025)

3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Oral Anti-diabetes Drugs Revenue

3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio

3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2024

3.5 Global Key Players of Oral Anti-diabetes Drugs Head office and Area Served

3.6 Global Key Players of Oral Anti-diabetes Drugs, Product and Application

3.7 Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Oral Anti-diabetes Drugs Breakdown Data by Type

4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2020-2025)

4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031)

5 Oral Anti-diabetes Drugs Breakdown Data by Application

5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Application (2020-2025)

5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Oral Anti-diabetes Drugs Market Size (2020-2031)

6.2 North America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)

6.4 North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oral Anti-diabetes Drugs Market Size (2020-2031)

7.2 Europe Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025)

7.4 Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2020-2031)

8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Oral Anti-diabetes Drugs Market Size (2020-2031)

9.2 Latin America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)

9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2020-2031)

10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sanofi

11.1.1 Sanofi Company Details

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction

11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.1.5 Sanofi Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction

11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.2.5 Eli Lilly Recent Development

11.3 AstraZeneca plc

11.3.1 AstraZeneca plc Company Details

11.3.2 AstraZeneca plc Business Overview

11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction

11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.3.5 AstraZeneca plc Recent Development

11.4 Astellas Pharma Inc

11.4.1 Astellas Pharma Inc Company Details

11.4.2 Astellas Pharma Inc Business Overview

11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction

11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.4.5 Astellas Pharma Inc Recent Development

11.5 Johnson & Johnson (Janssen Pharmaceuticals)

11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details

11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview

11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction

11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Details

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction

11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.6.5 Boehringer Ingelheim Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Oral Anti-diabetes Drugs Introduction

11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.7.5 Merck Recent Development

11.8 Takeda

11.8.1 Takeda Company Details

11.8.2 Takeda Business Overview

11.8.3 Takeda Oral Anti-diabetes Drugs Introduction

11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.8.5 Takeda Recent Development

11.9 Bristol Myers Squibb

11.9.1 Bristol Myers Squibb Company Details

11.9.2 Bristol Myers Squibb Business Overview

11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction

11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.9.5 Bristol Myers Squibb Recent Development

11.10 Novartis

11.10.1 Novartis Company Details

11.10.2 Novartis Business Overview

11.10.3 Novartis Oral Anti-diabetes Drugs Introduction

11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.10.5 Novartis Recent Development

11.11 Pfizer

11.11.1 Pfizer Company Details

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction

11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.11.5 Pfizer Recent Development

11.12 Abbott

11.12.1 Abbott Company Details

11.12.2 Abbott Business Overview

11.12.3 Abbott Oral Anti-diabetes Drugs Introduction

11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.12.5 Abbott Recent Development

11.13 Biocon

11.13.1 Biocon Company Details

11.13.2 Biocon Business Overview

11.13.3 Biocon Oral Anti-diabetes Drugs Introduction

11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.13.5 Biocon Recent Development

11.14 Sunpharma

11.14.1 Sunpharma Company Details

11.14.2 Sunpharma Business Overview

11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction

11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.14.5 Sunpharma Recent Development

11.15 Novo Nordisk

11.15.1 Novo Nordisk Company Details

11.15.2 Novo Nordisk Business Overview

11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction

11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.15.5 Novo Nordisk Recent Development

11.16 Piramal Healthcare

11.16.1 Piramal Healthcare Company Details

11.16.2 Piramal Healthcare Business Overview

11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction

11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.16.5 Piramal Healthcare Recent Development

11.17 Bayer Healthcare

11.17.1 Bayer Healthcare Company Details

11.17.2 Bayer Healthcare Business Overview

11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction

11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.17.5 Bayer Healthcare Recent Development

11.18 Dr. Reddy’s Laboratories Ltd

11.18.1 Dr. Reddy’s Laboratories Ltd Company Details

11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview

11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction

11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development

11.19 Glenmark Pharmaceuticals Ltd

11.19.1 Glenmark Pharmaceuticals Ltd Company Details

11.19.2 Glenmark Pharmaceuticals Ltd Business Overview

11.19.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction

11.19.4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)

11.19.5 Glenmark Pharmaceuticals Ltd Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Sanofi

Eli Lilly

Astrazeneca plc

Astellas Pharma Inc

Boehringer Ingelheim

Merck

Takeda

Bristol–Myers Squibb

Novartis

Pfizer Inc

Abbott

Biocon Ltd.

Sunpharma

Novo Nordisk

Piramal Healthcare

Bayer HealthCare

Dr. Reddy’s Laboratories Ltd.

Glenmark Pharmaceuticals Ltd

Johnson & Johnson (Janssen Pharmaceuticals)

List of Tables

Table 1. Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of by Type

Table 3. Key Players of by Drug Class

Table 4. Global Oral Anti-diabetes Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Oral Anti-diabetes Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Oral Anti-diabetes Drugs Market Share by Region (2020-2025)

Table 8. Global Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Oral Anti-diabetes Drugs Market Share by Region (2026-2031)

Table 10. Oral Anti-diabetes Drugs Market Trends

Table 11. Oral Anti-diabetes Drugs Market Drivers

Table 12. Oral Anti-diabetes Drugs Market Challenges

Table 13. Oral Anti-diabetes Drugs Market Restraints

Table 14. Global Oral Anti-diabetes Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Oral Anti-diabetes Drugs Market Share by Players (2020-2025)

Table 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)

Table 17. Ranking of Global Top Oral Anti-diabetes Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Oral Anti-diabetes Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Oral Anti-diabetes Drugs, Headquarters and Area Served

Table 20. Global Key Players of Oral Anti-diabetes Drugs, Product and Application

Table 21. Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Oral Anti-diabetes Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Oral Anti-diabetes Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Sanofi Company Details

Table 47. Sanofi Business Overview

Table 48. Sanofi Oral Anti-diabetes Drugs Product

Table 49. Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 50. Sanofi Recent Development

Table 51. Eli Lilly Company Details

Table 52. Eli Lilly Business Overview

Table 53. Eli Lilly Oral Anti-diabetes Drugs Product

Table 54. Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 55. Eli Lilly Recent Development

Table 56. AstraZeneca plc Company Details

Table 57. AstraZeneca plc Business Overview

Table 58. AstraZeneca plc Oral Anti-diabetes Drugs Product

Table 59. AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 60. AstraZeneca plc Recent Development

Table 61. Astellas Pharma Inc Company Details

Table 62. Astellas Pharma Inc Business Overview

Table 63. Astellas Pharma Inc Oral Anti-diabetes Drugs Product

Table 64. Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 65. Astellas Pharma Inc Recent Development

Table 66. Johnson & Johnson (Janssen Pharmaceuticals) Company Details

Table 67. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview

Table 68. Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Product

Table 69. Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 70. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development

Table 71. Boehringer Ingelheim Company Details

Table 72. Boehringer Ingelheim Business Overview

Table 73. Boehringer Ingelheim Oral Anti-diabetes Drugs Product

Table 74. Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 75. Boehringer Ingelheim Recent Development

Table 76. Merck Company Details

Table 77. Merck Business Overview

Table 78. Merck Oral Anti-diabetes Drugs Product

Table 79. Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 80. Merck Recent Development

Table 81. Takeda Company Details

Table 82. Takeda Business Overview

Table 83. Takeda Oral Anti-diabetes Drugs Product

Table 84. Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 85. Takeda Recent Development

Table 86. Bristol Myers Squibb Company Details

Table 87. Bristol Myers Squibb Business Overview

Table 88. Bristol Myers Squibb Oral Anti-diabetes Drugs Product

Table 89. Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 90. Bristol Myers Squibb Recent Development

Table 91. Novartis Company Details

Table 92. Novartis Business Overview

Table 93. Novartis Oral Anti-diabetes Drugs Product

Table 94. Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 95. Novartis Recent Development

Table 96. Pfizer Company Details

Table 97. Pfizer Business Overview

Table 98. Pfizer Oral Anti-diabetes Drugs Product

Table 99. Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 100. Pfizer Recent Development

Table 101. Abbott Company Details

Table 102. Abbott Business Overview

Table 103. Abbott Oral Anti-diabetes Drugs Product

Table 104. Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 105. Abbott Recent Development

Table 106. Biocon Company Details

Table 107. Biocon Business Overview

Table 108. Biocon Oral Anti-diabetes Drugs Product

Table 109. Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 110. Biocon Recent Development

Table 111. Sunpharma Company Details

Table 112. Sunpharma Business Overview

Table 113. Sunpharma Oral Anti-diabetes Drugs Product

Table 114. Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 115. Sunpharma Recent Development

Table 116. Novo Nordisk Company Details

Table 117. Novo Nordisk Business Overview

Table 118. Novo Nordisk Oral Anti-diabetes Drugs Product

Table 119. Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 120. Novo Nordisk Recent Development

Table 121. Piramal Healthcare Company Details

Table 122. Piramal Healthcare Business Overview

Table 123. Piramal Healthcare Oral Anti-diabetes Drugs Product

Table 124. Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 125. Piramal Healthcare Recent Development

Table 126. Bayer Healthcare Company Details

Table 127. Bayer Healthcare Business Overview

Table 128. Bayer Healthcare Oral Anti-diabetes Drugs Product

Table 129. Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 130. Bayer Healthcare Recent Development

Table 131. Dr. Reddy’s Laboratories Ltd Company Details

Table 132. Dr. Reddy’s Laboratories Ltd Business Overview

Table 133. Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Product

Table 134. Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 135. Dr. Reddy’s Laboratories Ltd Recent Development

Table 136. Glenmark Pharmaceuticals Ltd Company Details

Table 137. Glenmark Pharmaceuticals Ltd Business Overview

Table 138. Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Product

Table 139. Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)

Table 140. Glenmark Pharmaceuticals Ltd Recent Development

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

Table 144. Authors List of This Report

List of Figures

Figure 1. Oral Anti-diabetes Drugs Picture

Figure 2. Global Oral Anti-diabetes Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Oral Anti-diabetes Drugs Market Share by Type: 2024 VS 2031

Figure 4. by Type Features

Figure 5. by Drug Class Features

Figure 6. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Oral Anti-diabetes Drugs Market Share by Application: 2024 VS 2031

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Online Pharmacies Case Studies

Figure 11. Oral Anti-diabetes Drugs Report Years Considered

Figure 12. Global Oral Anti-diabetes Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Oral Anti-diabetes Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Oral Anti-diabetes Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Oral Anti-diabetes Drugs Market Share by Players in 2024

Figure 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Oral Anti-diabetes Drugs Revenue in 2024

Figure 18. North America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)

Figure 20. United States Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Oral Anti-diabetes Drugs Market Share by Country (2020-2031)

Figure 24. Germany Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Region (2020-2031)

Figure 32. China Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Sanofi Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 48. Eli Lilly Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 49. AstraZeneca plc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 50. Astellas Pharma Inc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 51. Johnson & Johnson (Janssen Pharmaceuticals) Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 53. Merck Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 54. Takeda Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 55. Bristol Myers Squibb Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 56. Novartis Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 57. Pfizer Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 58. Abbott Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 59. Biocon Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 60. Sunpharma Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 61. Novo Nordisk Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 62. Piramal Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 63. Bayer Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 64. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 65. Glenmark Pharmaceuticals Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oral Antidiabetic OAD Treatment Market Research Report 2024

Diabetes Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Antidiabetic Drugs Market Insights Forecast to 2030

Oral Medicines for Diabetes Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Antidiabetic Agents Market Insights Forecast to 2030

Oral Hypoglycemic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Diabetes Drugs Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global Diabetes Mellitus Treatment Market Insights Forecast to 2030

Injectable Drugs For Diabetes Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oral Hypoglycemic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Insulin Market Research Report 2025

Oral Hypoglycemic Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Anti diabetic Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Diabetes Medicines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Injectable Drugs For Type 2 Diabete Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Diabetes Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gestational Diabetes Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Type 2 Diabetes Medicines Market Research Report 2024

Diabetes Devices and Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions